There has been considerable interest in studying novel biomarkers in chronic kidney disease (CKD) beyond the conventional clinical indices, such as serum creatinine, blood urea nitrogen, and urine protein or urine albumin. The motivation for this is similar to what has been outlined in other articles in this issue of ASN Kidney News. For example, novel biomarkers may improve our ability to better risk classify patients and guide clinical actions (e.g., closer follow-up and more intense treatment for patients at higher risk of progression of CKD), to identify high-risk patients for enrollment into clinical trials (as enriched enrollment of patients who are more likely to progress will enhance study power), and to better understand underlying biological pathophysiological mechanisms (which may in turn identify novel targets for treatment).
Under the sponsorship of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a CKD Biomarker Consortium was formed in 2009. The consortium consists of investigators from more than a dozen academic medical centers and research institutions around the country, analyzing clinical data and stored biosamples and from numerous longitudinal cohorts.
Dr. Hsu is a member of the CKD Biomarker Consortium. Abbott had donated urine biomarker assays (NGAL) to the CKD Biomarker Consortium. Dr. Bansal is supported by K23 DK88865; Dr. Hsu by U01 DK85649 and K24 DK92291.